thin the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Act of 1934, as amended, relating to the
Company's growth strategy and prospects, revenues, gross margins, and
earnings, expenses, integrating the aesthetics business acquired from
Laserscope and realizing efficiencies and synergies relating thereto,
controlling costs, managing cash, and addressing our liquidity and capital
resource needs. Actual results could differ materially and adversely from
those projected in the forward-looking statements contained in our
Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the
fiscal year ended December 30, 2006 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this announcement are
made as of this date and will not be updated.
IRIDEX Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
Three Months Ended Nine Months Ended
September September September September
29, 30, 29, 30,
2007* 2006 2007* 2006
Sales $13,575 $9,222 $41,390 $26,869
Cost of sales 7,390 4,350 23,412 13,076
Gross profit 6,185 4,872 17,978 13,793
Operating expenses:
Research and development 1,319 1,506 4,636 3,955
Sales, general and administrative 5,920 4,854 21,740 12,651
Total operating expenses 7,239 6,360 26,376 16,606
Income (loss) from operations (1,054) (1,488) (8,398) (2,813)
Legal settlement
'/>"/>
SOURCE IRIDEX Corporation Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine news :1.
IRIDEX Announces Closing of $5.0 Million Private Placement2.
William Moore Appointed to IRIDEX Board of Directors3.
IRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor4.
James B. Hawkins Appointed to IRIDEX Board of Directors5.
Theodore A. Boutacoff Appointed President & CEO of IRIDEX6.
IRIDEX Announces Third Quarter 2007 Conference Call and Release Date7.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites8.
Haemacure Reports Third Quarter 2007 Results9.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion10.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best11.
MDS Reports Third Quarter 2007 Results